Figure 1
From: Combination of palbociclib and radiotherapy for glioblastoma

Treatment of patient-derived cell lines (PDCLs) with palbociclib. (a) Expression of retinoblastoma protein (Rb1) pathway proteins in PDCLs without treatment; (b) Dose-response curves of the PDCLs treated with increasing concentrations of palbociclib; (c) Median IC50 doses of palbociblib for each PDCL. All experiments were repeated three times. Error bars represent the standard deviation of the mean.